Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide

What Was Tested

The paper reports a study of Teduglutide (GLP-2 analog), published as a randomized controlled trial.

The complex care needs of pediatric patients with short bowel syndrome-associated intestinal failure (SBS-IF) can negatively impact the health-related quality of life (HRQoL) of patients and their caregivers.

The researchers assessed the impact of teduglutide on HRQoL of pediatric patients with SBS-IF.

Why It Was Studied

Clinical trials NCT02949362 and NCT02954458.

Who Took Part

PubMed indexes the participants as young children, children and teenagers, both men and women.

Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Teduglutide (GLP-2 analog) group and the comparison group should start out alike.

The methods mention a period of 96 weeks.

Two long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module.

The researchers assessed changes in HRQoL over time, as well as the impact of attaining enteral autonomy on HRQoL and predictors of change in HRQoL.

What Was Measured

The subject headings attached to it are Short Bowel Syndrome, Quality of Life, Intestinal Failure, Peptides and Gastrointestinal Agents.

The authors tagged it with the keywords gastroenterology, glucagon‐like peptide‐2 and outcomes research/quality.

What This Means in Plain Language

The paper is a randomized study of Teduglutide (GLP-2 analog) over 96 weeks.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Journal of pediatric gastroenterology and nutrition), a journal based in United States.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.